Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance

Gilead Sciences, Inc.Trade
Direxion NASDAQ 100 Equal Weighted Index SharesTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Gilead Sciences, Inc. trades at $136.22 (market cap $168.35B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.18. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDQQQE
Market Cap
$168.35B
Sector
HealthBroad Market / Factor
52-Week High
$155.80$122.72
52-Week Low
$110.56$96.06
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $123.01, up 0.7% today, with a bullish technical signal from moving averages. The fund provides diversified exposure to the Nasdaq-100 with equal weighting, reducing concentration risk compared to cap-weighted peers. Recent news highlights its appeal as a defensive play amid tech-led market rallies and the upcoming inclusion of SpaceX in the index.

The outlook remains positive given equal-weight diversification benefits and strong Nasdaq-100 growth trends. Key risks include market volatility and sector concentration, but analyst sentiment favors QQQE for balanced Nasdaq exposure. The ETF's structure mitigates single-stock risk while capturing broad large-cap growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Direxion NASDAQ 100 Equal Weighted Index Shares

QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.

Read more on QQQE